<DOC>
	<DOC>NCT00825565</DOC>
	<brief_summary>The purpose of this study is to determine how safe and effective allantoin 3% cream (Alwextin) is in improving the healing of recurrent skin lesions and reducing overall blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically to the entire body once daily.</brief_summary>
	<brief_title>Study of AlwextinÂ® Cream in Treating Epidermolysis Bullosa</brief_title>
	<detailed_description>Potential subjects came to the for a screening visit. Eligible subjects had baseline assessments performed and were provided study medication, allantoin 3% cream. Subjects were instructed to apply the study medication to the entire body once daily and to keep daily record of study medication use. Subjects returned every 4 weeks for a total of 12 weeks for repeat assessments.</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Allantoin</mesh_term>
	<criteria>history of epidermolysis bullosa use of any skin product containing allantoin for 30 days prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Epidermolysis bullosa</keyword>
</DOC>